Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001589720 | SCV001814307 | uncertain significance | not provided | 2021-05-25 | criteria provided, single submitter | clinical testing | Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV002506689 | SCV002814683 | uncertain significance | Autism, susceptibility to, 15; Cortical dysplasia-focal epilepsy syndrome | 2022-03-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002570840 | SCV003254712 | uncertain significance | Cortical dysplasia-focal epilepsy syndrome | 2022-03-15 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 982 of the CNTNAP2 protein (p.Glu982Gly). This variant is present in population databases (rs752419100, gnomAD 0.009%). This variant has not been reported in the literature in individuals affected with CNTNAP2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1213132). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |